On October 16, 2025, ATAI Life Sciences N.V. received FDA Breakthrough Therapy designation for BPL-003, a treatment showing significant improvement for patients with treatment-resistant depression, demonstrating effectiveness in reducing symptoms within 24 hours. This designation highlights its potential to transform the treatment landscape for this condition.